Roche to acquire liver drug developer 89bio for €2.4bn
Roche has agreed to buy US biotech firm 89bio for up to $3.5 billion to strengthen its development pipeline of liver and cardiometabolic disease treatments, the Swiss drugmaker said today.
Business
• 2 hrs
